Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 1

2(33.3%)

6Total

Phase 2(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05552755Phase 1Recruiting

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

Role: lead

NCT06005974Phase 2Terminated

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

Role: lead

NCT06678659Phase 1Recruiting

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Role: lead

NCT06536465Phase 2Terminated

The Clostridioides Difficile Trial of REC-3964

Role: lead

NCT05130866Phase 2Terminated

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Role: lead

NCT05085561Phase 2Completed

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

Role: lead

All 6 trials loaded